Ignite Creation Date:
2025-12-24 @ 5:43 PM
Ignite Modification Date:
2025-12-25 @ 3:12 PM
Study NCT ID:
NCT03253068
Status:
UNKNOWN
Last Update Posted:
2020-05-19
First Post:
2017-08-12
Is NOT Gene Therapy:
False
Has Adverse Events:
False
Brief Title:
Pembrolizumab Plus Amurubicin in Patients With Refractory Small-cell Lung Cancer
Sponsor:
Wakayama Medical University
Organization:
Study Overview
Official Title:
A Phase II Study of Pembrolizumab Plus Amurubicin in Patients With Refractory Small-cell Lung Cancer
Status:
UNKNOWN
Status Verified Date:
2020-05
Last Known Status:
ACTIVE_NOT_RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
To explore the overall response rate (ORR) per RECIST 1.1 as assessed by investigators in subjects with refractory small cell lung cancer treated with pembrolizumab (Pembro) plus amurubicin (AMR).
Detailed Description:
Open, uncontrolled, multi-center, phase II study.
Study Oversight
Has Oversight DMC:
True
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?: